Trulicity (Dulaglutide) Does Not Cause Drowsiness
Drowsiness is not a recognized side effect of Trulicity (dulaglutide). Based on comprehensive guideline evidence and FDA labeling, the most common adverse effects are gastrointestinal in nature—specifically nausea, vomiting, diarrhea, abdominal pain, and decreased appetite 1, 2.
Common Side Effects to Expect
The adverse effect profile of dulaglutide is well-characterized and consistent across clinical trials and real-world studies:
- Gastrointestinal effects (most common): nausea, vomiting, diarrhea, constipation, abdominal pain 1, 2, 3
- Metabolic effects: decreased appetite 2
- Injection site reactions 1
These GI side effects are typically mild to moderate, self-limiting, and can be mitigated through slow dose titration and avoiding overeating 1, 4.
What About Dizziness?
While dizziness is listed as a potential side effect in obesity management guidelines for semaglutide 5, this is distinct from drowsiness and appears related to volume depletion or hypoglycemia rather than central nervous system sedation. For dulaglutide specifically, dizziness may occur as a symptom of hypoglycemia when combined with insulin or sulfonylureas 2, but this is a metabolic effect, not a sedating one.
Serious Adverse Effects to Monitor
While not causing drowsiness, be vigilant for:
- Pancreatitis: Severe abdominal pain that won't resolve 1, 2
- Gallbladder disease: Upper abdominal pain, jaundice 1, 2
- Hypoglycemia: When combined with insulin or sulfonylureas—symptoms include dizziness, confusion, shakiness 2
- Delayed gastric emptying: Important consideration before surgery or procedures requiring anesthesia 6, 2
- Kidney problems: From dehydration due to GI side effects 2
Clinical Implications
If a patient reports drowsiness while taking Trulicity, look elsewhere for the cause. Consider:
- Other medications (particularly if recently added)
- Uncontrolled diabetes causing fatigue
- Sleep disorders
- Depression or other psychiatric conditions
- Thyroid dysfunction
- Anemia or other metabolic abnormalities
The psychiatric safety profile of GLP-1 RAs has been scrutinized, with some signals for depression and anxiety with semaglutide 7, but drowsiness or sedation is not part of this concern and has not been reported for dulaglutide.